Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Clinical Update

Treating obsessive-compulsive and tic disorders

Erica Weir
CMAJ July 11, 2000 163 (1) 82;
Erica Weir
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Background

Obsessive-compulsive disorder (OCD) and tic disorders are common in childhood, affecting 1% to 2% of school-aged children and adolescents. Treatment with serotonin-reuptake inhibitors, behaviour therapy, or both, helps more than 75% of these patients, but most show only partial response and relapse when medication is discontinued. The cause of OCD and tic disorders is unknown. Poststreptococcal autoimmunity has been postulated as a possible environmental trigger, raising the possibility that some children might respond to immunomodulatory therapy.

Question

Is plasma exchange or intravenous immunoglobulin (IVIG) better than placebo in decreasing neuropsychiatric symptoms in children with exacerbations of OCD or tics triggered by streptococcal infection?

Design

The study was a randomized, placebo-controlled trial with follow-up at 1 month and 1 year. Children between the ages of 5 and 14 years, with an existing severe exacerbation of OCD or tic disorder and a history of exacerbations associated with streptococcal infection, were randomly assigned to treatment with plasma exchange (5 single-unit exchanges over 2 weeks), IVIG (1g/kg on 2 consecutive days) or placebo (intravenous saline). Symptom severity was rated on standard scales at baseline, 1 month and 12 months (active treatment groups only) after treatment. Neuropsychiatric medications were maintained at constant doses over the first month and were then adjusted as needed.

Results

Thirty children participated in the study; 10 received plasma exchange (2 subjects were lost to follow-up at 12 months), 10 received IVIG (1 subject withdrew within a month) and 10 received placebo. At baseline patient characteristics and symptom severity were similar, with the exception that tics were more severe among children in the plasma-exchange group. Mild-to-moderate adverse reactions were experienced by 12 of the 19 subjects in the active treatment groups (e.g., nausea, vomiting and headache) and by 2 in the placebo group (e.g., stomach ache and headache). At 1 month the IVIG and plasma-exchange groups showed a mean improvement from baseline of 45% (OC scale score reduction of 12) and 58% (OC scale score reduction of 13) respectively, while children in the control group improved a mean of 3% (OC score reduction of 0.9); overall function scores were 2.9 (33% improvement), 2.8 (35% improvement) and 0 (no change) for the respective groups. Symptom improvement usually occurred by 1 week in the plasma-exchange group and by 3 weeks in the IVIG group. Tic symptoms improved significantly in the plasma-exchange group only. At 12 months 14 of the 17 children who had received active treatment were much or very much improved.

Commentary

Postinfectious autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) are believed to be mediated by antibodies formed after group A β-hemolytic streptococcal infection that cross-react with neuronal tissue.1 Sydenham's chorea, the neurological manifestation of rheumatic fever, has been proposed as a potential model of pathophysiology.2 The original hypothesis of the study was that either IVIG or plasma exchange would reduce symptom severity by blocking (IVIG) or removing (plasma exchange) the antibodies that are cross-reacting. Despite limitations, such as the lack of blinding to treatment assignment,3 the study demonstrated that both interventions effectively reduced symptoms in a select population of children with a history of streptococcal-induced symptom exacerbation. According to this hypothesis, however, the rate of symptom improvement should be directly proportional to the rate of antibody removal. Most of the children receiving plasma exchange did not show immediate improvement, suggesting that the mechanism of immunomodulation is not well understood.

Clinical implications

This study does not support the routine use of immunomodulatory agents to treat OCD and tic disorders but does prompt intriguing questions for further study and review.4

References

  1. 1.↵
    Swedo S, Henrietta L, Barbara M, Allen A, Rapoport J, Dow S, et al. Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Am J Psychiatry 1997;154:110-2.
    OpenUrlPubMed
  2. 2.↵
    Swedo S. Sydenham's chorea - a model for childhood autoimmune neuropsychiatric disorders. JAMA 1994;272:1788-91.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Singer H. PANDAS and immunomodulatory therapy. Lancet 1999;354:1137-8.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Goodman WK. Obsessive-compulsive disorder: diagnosis and treatment. J Clin Psychiatry 1999;60(S18):27-32.
  5. Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, Leonard HL, Swedo SE. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999;354:1153-8.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

CMAJ
Vol. 163, Issue 1
11 Jul 2000
  • Table of Contents
  • Index by author
  • Canadian Adverse Drug Reaction Newsletter (85-92)

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treating obsessive-compulsive and tic disorders
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Treating obsessive-compulsive and tic disorders
Erica Weir
CMAJ Jul 2000, 163 (1) 82;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Treating obsessive-compulsive and tic disorders
Erica Weir
CMAJ Jul 2000, 163 (1) 82;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Background
    • Question
    • Design
    • Results
    • Commentary
    • Clinical implications
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Early treatment of acute hepatitis C infection may lead to cure
  • Angiotensin-II–receptor blockers and nephropathy in patients with type 2 diabetes
  • Colorectal cancer screening: you can't be positive about a negative result
Show more Clinical Update

Similar Articles

Collections

  • Topics
    • Drugs: immunologic
    • Psychiatry & mental health: adult
    • Psychiatry & mental health: child & adolescent

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire